Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) have announced that a late-stage replicate trial for their interleukin blocker Dupixent (dupilumab) has successfully met its primary endpoint during an interim analysis. The trial demonstrated a significant reduction in exacerbations over 52 weeks in patients with chronic obstructive pulmonary disease (COPD) compared to maximal standard-of-care. The 34% reduction aligns with the 30% reduction reported earlier this year in a landmark trial, further validating Dupixent’s potential to transform the treatment of moderate-to-severe COPD.
According to the press release, the biologic also showed a significant improvement in lung function compared to placebo, with benefits sustained over the 52-week period. The companies now intend to submit these data by the end of the year in the US, where Dupixent currently holds breakthrough therapy designation (BTD) based on results from the previous trial.- Flcube.com
